Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

for this reason. The overall rate of discontinuation due to adverse events was 16%(1).

About LBH589Because it is an investigational compound, the safety and efficacy profile of LBH589 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of uncertainty of clinical trials, there is no guarantee that LBH589 will ever be commercially available anywhere in the world.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "investigational," "potential," "investigating," "ongoing," "encouraging," "committed," "promising," or similar expressions, or by express or implied discussions regarding potential future approvals to market LBH589, or regarding potential future revenues from LBH589. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that LBH589 will be submitted or approved for sale in any market, or that LBH589 will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... WOONSOCKET, R.I , April 17, 2015 ... holding a conference call on Friday, May 1, 2015, ... discuss its first quarter financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://investors.cvshealth.com . This webcast will be ...
(Date:4/17/2015)... April 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) ... that clinical data presented at the 2015 European ... Precision Cancer Monitoring ℠ (PCM) platform outperformed ... EGFR T790M mutations in metastatic lung ... EGFR T790M Mutation in Urinary Circulating Tumor DNA ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
(Date:4/18/2015)... For some people, tattoos are works of art that ... their lives, as they have spent a great deal of ... amount of thought on their designs. For others, however, tattoos ... simply want them removed for personal or professional reasons. In ... 2012-13 there was a 43 percent increase in the number ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancehints.com has released ... insurance plans that offer financial protection against fire damage. ... will pay benefits in case their vehicle is set intentionally ... vandalism caused by rioting or by other things. , ... quotes on a single website http://www.carinsurancehints.com/ , in ...
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog ... auto insurance prices . , Drivers who ... theft may have to pay more for auto insurance ... policies can also offer protection against vehicle theft. ... online on a single website: http://lowcostcarinsuranceprice.com/ . ...
(Date:4/18/2015)... More than 2000 styles of newly ... the #1 online store carrying celebrity inspired special occasion ... got their perfect dresses for their prom. For those ... dresses at TheCelebrityDresses.com would be an ideal choice. ... prom dresses inspired by the most loved styles seen ...
(Date:4/18/2015)... Montreal, Canada (PRWEB) April 18, 2015 ... of emotions on food choices when he uttered, “Tell ... what you are.” Using food to cope with stress ... research by Queendom.com indicates otherwise. Data collected ... both genders fall victim to emotional eating, but for ...
Breaking Medicine News(10 mins):Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... , OAKLAND, Calif., Aug. 5 Anyone ... record in a standardized format understood at hospitals, clinics and ... specializing in chronic illness support, geriatric care management and private ... Your Own Health to re-brand and sell the popular ...
... , , PHOENIX, Aug. 5 ... hand must not become a vehicle for taking lives through abortion ... report at the organization,s 127th annual convention here today. Referring to ... declared that "Health care reform must be abortion-free." , , ...
... direction for diabetes treatment , WEDNESDAY, Aug. 5 (HealthDay News) ... role in the control of blood sugar production in the ... first time that CCK from the gut activates receptors to ... axis," Tony Lam of the University of Toronto said in ...
... , , , ... a privately-held specialty pharmaceutical company, today announced that it has ... IMS data indicates the combined U.S. market for these two ... and shipping both products immediately. , , ...
... an animal model that provides strong evidence why imatinib, marketed ... but does not keep the disease from returning if treatment ... drug,s radar and enable the disease to recur in most ... issue of Cancer Cell . The researchers ...
... An internationally recognized Virginia Commonwealth University physician has ... Award for his pioneering contributions that have advanced the ... past recipients who have made a remarkable impact on ... Foundation for Infectious Diseases awarded the honor to Richard ...
Cached Medicine News:Health News:Portable Health Care Records Now Available for Consumers 2Health News:'Health Care Reform Must be Abortion-Free,' says Supreme Knight 2Health News:Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection 2Health News:Finding key to cancer drug Gleevec's limitations 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 3
... 5 system is an intuitive, all-in-one ... to minimize the scarring and risk ... procedures. Incorporating an enhanced, ergonomic handle ... operative obstructions, this new device is ...
... The Arrow LionHeart Left Ventricular Assist System ... designed to be used as a destination ... (Class IV) congestive heart failure, for which ... Arrow LionHeart LVAS is not intended as ...
... The TandemHeart PTVA ( Percutaneous ... proprietary solution for the hemodynamic needs of ... and Cardiac Surgeons. These specialists have ... some coronary artery perfusion, but the IABP ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Medicine Products: